News Image

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

Provided By GlobeNewswire

Last update: Feb 16, 2024

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share. The offering raised aggregate gross proceeds of approximately $6.6 million, prior to deducting underwriting discounts and other offering expenses.

Read more at globenewswire.com

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (2/21/2025, 8:08:47 PM)

After market: 1.74 +0.06 (+3.57%)

1.68

+0.05 (+3.07%)



Find more stocks in the Stock Screener

Follow ChartMill for more